Tanibirumab (TTAC-0001): A Fully Human Monoclonal Antibody Targets Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2)

被引：29
|
作者：
Lee, Sang Hoon [1 ]
机构：
[1] PharmAbcine, Taejon 305811, South Korea
来源：
ARCHIVES OF PHARMACAL RESEARCH | 2011年 / 34卷 / 08期
关键词：
TUMOR ANGIOGENESIS; THERAPY; DISEASE;
D O I：
10.1007/s12272-011-0821-9
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Vascular endothelial growth factor (VEGF) binds to its receptor (VEGFR) and stimulates angiogenesis, an important step in tumor growth and metastasis. Several anticancer therapies targeting VEGFR with small molecules and antibody have been currently studied in preclinical and clinical studies. This article provides a review of human monoclonal antibody tanibirumab (TTAC-0001), which specifically binds VEGFR-2 and is currently being developed in preclinical stage by PharmAbcine (Daejon, Korea).
引用
收藏
页码：1223 / 1226
页数：4
相关论文
共 50 条
  • [21] Anti-angiogenic Agents: A Review on Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Inhibitors
    Cheng, Kang
    Liu, Chen-Fu
    Rao, Guo-Wu
    CURRENT MEDICINAL CHEMISTRY, 2021, 28 (13) : 2540 - 2564
  • [22] Vascular endothelial growth factor receptor-2 (VEGFR-2) N-glycosylation modulates angiogenic signaling
    Chandler, Kevin B.
    Leon, Deborah R.
    Meyer, Rosana D.
    Rahimi, Nader
    Costello, Catherine E.
    CANCER RESEARCH, 2017, 77
  • [23] Vascular endothelial growth factor receptor 2 (VEGFR-2) signalling activity in paediatric pilocytic astrocytoma is restricted to tumour endothelial cells
    Sikkema, A. H.
    de Bont, E. S. J. M.
    Molema, G.
    Dimberg, A.
    Zwiers, P. J.
    Diks, S. H.
    Hoving, E. W.
    Kamps, W. A.
    Peppelenbosch, M. P.
    den Dunnen, W. F. A.
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2011, 37 (05) : 538 - 548
  • [24] Receptor chimeras indicate that the vascular endothelial growth factor receptor-1 (VEGFR-1) modulates mitogenic activity of VEGFR-2 in endothelial cells
    Rahimi, N
    Dayanir, V
    Lashkari, K
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (22) : 16986 - 16992
  • [25] Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes
    Cooper, ME
    Vranes, D
    Youssef, S
    Stacker, SA
    Cox, AJ
    Rizkalla, B
    Casley, DJ
    Bach, LA
    Kelly, DJ
    Gilbert, RE
    DIABETES, 1999, 48 (11) : 2229 - 2239
  • [26] Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing
    Gan, LS
    Fagerholm, P
    Palmblad, J
    ACTA OPHTHALMOLOGICA SCANDINAVICA, 2004, 82 (05): : 557 - 563
  • [27] In-silico screening and In-vitro validation of Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) inhibitors
    Saraswat, Deepika
    Nehra, Sarita
    Chaudhary, Kamal Kumar
    Prasad, C. V. S. Siva
    BIOINFORMATION, 2014, 10 (05) : 273 - 280
  • [28] Genes Encoding Vascular Endothelial Growth Factor A (VEGF-A) and VEGF Receptor 2 (VEGFR-2) and Risk for Bronchopulmonary Dysplasia
    Mahlman, Mari
    Huusko, Johanna M.
    Karjalainen, Minna K.
    Kaukola, Tuula
    Marttila, Riitta
    Ojaniemi, Marja
    Haataja, Ritva
    Lavoie, Pascal M.
    Ramet, Mika
    Hallman, Mikko
    NEONATOLOGY, 2015, 108 (01) : 53 - 59
  • [29] The phosphorylation of vascular endothelial growth factor receptor-2 (VEGFR-2) by engineered surfaces with electrostatically or covalently immobilized VEGF
    Anderson, Sean M.
    Chen, Tom T.
    Iruela-Arispe, M. Luisa
    Segura, Tatiana
    BIOMATERIALS, 2009, 30 (27) : 4618 - 4628
  • [30] Trasforming growth factor-β1 (TGF-β1) counteracts the protective effect of vascular endothelial growth factor receptor 2 (VEGFR-2) in human glomerular endothelial cells (GENC).
    Pala, L
    Cresci, B
    Giannini, S
    Manuelli, C
    Cappugi, P
    Rotella, CM
    DIABETOLOGIA, 2001, 44 : A265 - A265
12345